AI-generated content for informational purposes only. Not financial advice. Always do your own research.

Om

Intuitive Surgical, Inc. (NASDAQ: ISRG) er den globale lederen innen robotassistert minimalt invasiv kirurgi, mest kjent for sine da Vinci-kirurgisystemer som brukes i millioner av inngrep over hele verden innen urologi, gynekologi, hjerte-thoraxkirurgi og generell kirurgi. Selskapet genererer tilbakevendende inntekter fra instrumenter, tilbehør og tjenester knyttet til sin store installerte base av robotsystemer. Intuitive Surgical er en førsteklasses aksje i skjæringspunktet mellom robotikk og helsevesen, og tilbyr investorer eksponering mot den økende bruken av kirurgisk robotikk med en dominerende markedsposisjon og en barberhøvel-og-blad inntektsmodell.

Aksjer knyttet til aldrende befolkning

Intuitive Surgicals da Vinci robotkjirurgiplattform blir stadig mer essensiell ettersom aldrende befolkninger driver etterspørselen etter minimalinvasive kirurgiske prosedyrer med raskere gjenopprettingstider.

Helseaksjer

Intuitive Surgical er en helseaksje på skjæringspunktet mellom medisinsk teknologi og innovasjon, med dets da Vinci robotkjirurgisystemer installert på sykehus verden over som utfører millioner av minimalinvasive prosedyrer årlig, og genererer høy-margin tilbakeholdende inntekter fra instrumenter, tilbehør og servicekontrakter som vokser med hvert system som blir installert.

Robotikkaksjer

Intuitive Surgical er den dominerende robotikk-aksjen innen kirurgisk automatisering, med sine da Vinci-systemer som definerer standarden for robotassistert kirurgi. Dets massive installert base, tilbakeholdende inntekter fra forbruksartikler og ekspansjon til nye prosedyretyper gjør det til den beste rent fokuserte robotikkinvesteringen innen medisinsk felt.

Key Financials ISRG

Pris $485.84
Endring (1D) +1.51%
Endring (30D) -14.22%
Endring (60D) -11.13%
Endring (90D) +8.04%
Endring (180D) -12.05%
Endring (1Y) -17.60%
Endring (5Y) +87.02%
P/E-forhold 71.45
EPS (TTM) $6.80
52-ukers rekkevidde $425.00 — $609.08
50-dagers MA $542.29
Volum 1.98M

Data updated Feb 15 · Source: Twelve Data

4.8
2 reviews
Demographic Exposure
4.8
Growth Potential
4.5
Financial Stability
4.2
Regulatory Risk
3.8
Dividend Reliability
2.5
Claude Opus 4.6
AI Review
4.6/5

Intuitive Surgical is the undisputed leader in robotic-assisted surgery, with its da Vinci surgical systems installed in thousands of hospitals worldwide. The company benefits from a powerful razor-and-blade model"recurring revenue from instruments and accessories grows as its installed base expands. With an EPS of $6.80 and strong procedure volume growth, fundamentals remain solid.

The bull case centers on an aging population driving surgical demand, expanding indications for robotic procedures, and the recent launch of the da Vinci 5 platform. Intuitive's competitive moat"built on surgeon training, regulatory approvals, and ecosystem lock-in"remains formidable despite emerging competitors like Medtronic's Hugo.

The bear case is valuation. At a P/E of 71.45, the stock prices in years of flawless execution. The recent 17.6% decline from 52-week highs reflects this vulnerability, and trading below its 50-day MA signals near-term momentum weakness. Any slowdown in procedure growth or hospital capital spending could pressure shares significantly.

A best-in-class robotics franchise, but investors must be comfortable paying a premium multiple for quality.

Demographic Exposure
4.8
Growth Potential
4.5
Financial Stability
4.2
Regulatory Risk
3.8
Dividend Reliability
2.5
Feb 15, 2026
Gemini 3 Pro Preview
AI Review
4.9/5

Intuitive Surgical (ISRG) remains the undisputed leader in the robotic-assisted surgery market, anchored by its ubiquitous da Vinci systems. The company enjoys a formidable economic moat driven by high switching costs and a lucrative "razor-and-blade" recurring revenue model derived from disposable instruments and services. While the fundamental growth story regarding procedure adoption remains intact, valuation is a primary concern. With a P/E ratio of nearly 78, the stock trades at a significant premium that demands flawless execution. Currently trading below its 50-day moving average of $547.25 and off its 52-week highs, the recent pullback may offer a more attractive entry point for long-term investors willing to weather volatility. However, risks include potential constraints on hospital capital spending and emerging competition from larger medtech rivals. ISRG is a high-quality compounder, but investors must be mindful of its rich valuation.

Feb 11, 2026

Latest from Otrai